Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation

B H Chong1

  • 1Haematology Department, Prince of Wales Hospital.

Australian Family Physician
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

This review covers anticoagulation drugs that prevent blood clots and clot-lysing drugs that dissolve them. It examines traditional agents like warfarin and heparin, alongside newer options such as low molecular weight heparins and recombinant tissue plasminogen activator.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk.

Journal of autoimmunity·2021
Same author

Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis.

International journal of laboratory hematology·2018
Same author

Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process.

Clinical & experimental metastasis·2015
Same author

Recommendations for the use of the non-obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug-induced thrombocytopenia: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Beware of NK cells in pre-clinical metastasis models.

Clinical & experimental metastasis·2013
Same author

EGFR and the complexity of receptor crosstalk in the cardiovascular system.

Current molecular medicine·2012
Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018
Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018
Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018
Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018
Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018
Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Thrombosis Research

Background:

  • Anticoagulation therapy is crucial for managing thromboembolic disorders.
  • Understanding drug mechanisms is key to effective treatment.
  • Advances in anticoagulant and thrombolytic agents offer improved therapeutic options.

Purpose of the Study:

  • To review established and novel anticoagulant and thrombolytic medications.
  • To provide an overview of drug classes and their clinical applications.
  • To highlight key agents in thrombosis management.

Main Methods:

  • Literature review of anticoagulation and clot lysis drugs.
  • Inclusion of traditional agents (warfarin, heparin, streptokinase).
  • Discussion of newer agents (LMW heparins, r-tPA).

Related Experiment Videos

Main Results:

  • Comprehensive overview of drugs inhibiting clot formation.
  • Detailed examination of drugs inducing clot lysis.
  • Comparison of mechanisms and applications of various anticoagulants and thrombolytics.

Conclusions:

  • The field of anticoagulation encompasses diverse drug classes.
  • Both clot prevention and clot dissolution strategies are vital.
  • Emerging agents offer enhanced efficacy and safety profiles in managing thrombotic conditions.